Who Paid My Doc
Samuel Moore
Neurocritical Care Knoxville, TN Medical Doctor
NPI 1467684621 CMS profile 747028
501 20Th St, Ste 503, Knoxville, TN 37916
General payments
$22
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$8,320
Through program year 2025, Samuel Moore of Knoxville, TN is reported in the CMS Open Payments database as having received $22 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,320 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 5th percentile of Neurocritical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22 | 1 |
Beside peers
- Samuel Moore
- Neurocritical Care median
- Middle half of Neurocritical Care
- National median
In program year 2025, general payments to Samuel Moore were reported at $22. Among 223 Neurocritical Care profiles paid that year, the median was $98 and the middle half received between $34 and $262.
Show as a table
| Year | Samuel Moore | Neurocritical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $125 | $47–$286 | $163 |
| 2020 | $0 | $74 | $21–$153 | $114 |
| 2021 | $0 | $108 | $34–$250 | $132 |
| 2022 | $0 | $115 | $31–$277 | $149 |
| 2023 | $0 | $127 | $35–$275 | $160 |
| 2024 | $0 | $127 | $44–$265 | $164 |
| 2025 | $22 | $98 | $34–$262 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
55
Drug cost
$14,475
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ubrelvy Ubrogepant | Brand | 12 | $13,571 | |
| Gabapentin | Generic | 20 | $721 | |
| Donepezil Hcl | Generic | 23 | $183 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$35,782
Medicare patients
255
Services billed
367
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Ischemic heart disease | 42% | |
| Atrial fibrillation | 40% | |
| Chronic kidney disease | 39% | |
| Depression | 39% | |
| Diabetes | 38% | |
| Alzheimer's or dementia | 34% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurocritical Care in Tennessee
Related records
Neurocritical Care in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Neurocritical Care
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.